Segment Reporting The Company operates in three major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of ancillary services and the operation of optical services. "All other" primarily consists of the Company's corporate general and administrative functions. The following tables present financial information for each reportable segment (in thousands): Successor Predecessor Successor Predecessor Three Months Ended September 30, September 1 to September 30, July 1 to August 31, Nine Months Ended September 30, January 1 to August 31, 2018 2017 2017 2018 2017 Revenues: Surgical facility services $ 420,514 $ 125,595 $ 167,765 $ 1,234,984 $ 688,725 Ancillary services 20,719 5,775 4,409 62,655 52,261 Optical services 2,699 888 1,905 8,437 7,629 Total $ 443,932 $ 132,258 $ 174,079 $ 1,306,076 $ 748,615 Adjusted EBITDA (1) : Surgical facility services $ 74,525 $ 20,947 $ 27,726 $ 216,540 $ 125,912 Ancillary services 875 (1,265 ) (10,737 ) 2,925 (6,526 ) Optical services 571 193 555 2,087 2,214 All other (16,983 ) (5,033 ) (9,142 ) (60,087 ) (36,036 ) Total $ 58,988 $ 14,842 $ 8,402 $ 161,465 $ 85,564 (1) When the Company uses the term Adjusted EBITDA, it is referring to income before income taxes adjusted for (a) net income attributable to non-controlling interests, (b) depreciation and amortization, (c) interest expense, net, (d) equity-based compensation, (e) contingent acquisition compensation expense, (f) transaction, integration and acquisition costs, (g) gain on litigation settlement, (h) gain on acquisition escrow release, (i) reserve adjustments, (j) loss on disposals and deconsolidations, net, (k) gain on amendment to tax receivable agreement and (l) loss on debt refinancing. Adjusted EBITDA is the primary profit/loss metric reviewed by the chief operating decision maker in making key business decisions and on allocation of resources. Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating the Company's financial performance. The Company's calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. A reconciliation of Adjusted EBITDA to income before income taxes included in the condensed consolidated statement of operations is as follows: Successor Predecessor Successor Predecessor Three Months Ended September 30, September 1 to September 30, July 1 to August 31, Nine Months Ended September 30, January 1 to August 31, 2018 2017 2017 2018 2017 Adjusted EBITDA $ 58,988 $ 14,842 $ 8,402 $ 161,465 $ 85,564 Net income attributable to non-controlling interests 23,000 6,492 8,813 69,418 42,087 Depreciation and amortization (16,945 ) (3,330 ) (7,599 ) (49,379 ) (30,124 ) Interest expense, net (37,159 ) (15,883 ) (18,147 ) (107,368 ) (68,929 ) Equity-based compensation (1,526 ) (1,683 ) (1,628 ) (6,303 ) (3,697 ) Contingent acquisition compensation expense (503 ) (605 ) (1,210 ) (1,510 ) (5,057 ) Transaction, integration and acquisition costs (1) (7,489 ) (3,457 ) (2,949 ) (25,419 ) (7,677 ) Gain on litigation settlement     3,794 Gain on acquisition escrow release   1,000  1,000 Reserve adjustments (2) 2,109   (2,670 )  Loss on disposals and deconsolidations, net (12,631 ) (333 ) (114 ) (15,875 ) (1,715 ) Gain on amendment to tax receivable agreement  1,098 15,294  15,294 Loss on debt refinancing   (18,211 )  (18,211 ) Income before income taxes $ 7,844 $ (2,859 ) $ (16,349 ) $ 22,359 $ 12,329 (1) This amount includes transaction and integration costs of $7.1 million and $23.8 million for the three and nine months ended September 30, 2018 (Successor), respectively, $3.0 million for the one month ended September 30, 2017 (Successor), and $2.3 million and $5.6 million for the two and eight months ended August 31, 2017 (Predecessor), respectively. This amount includes acquisition costs of $0.4 million and $1.6 million for the three and nine months ended September 30, 2018 (Successor), respectively, $0.5 million for the one month ended September 30, 2017 (Successor), and $0.6 million and $2.1 million for the two and eight months ended August 31, 2017 (Predecessor), respectively. (2) This amount represents adjustments to revenue in connection with applying consistent policies across the combined company as a result of the integration of Surgery Partners and NSH. Successor September 30, 2018 December 31, 2017 Assets: Surgical facility services $ 4,015,094 $ 4,072,521 Ancillary services 110,588 104,274 Optical services 34,811 48,309 All other 398,171 397,669 Total assets $ 4,558,664 $ 4,622,773 Successor Predecessor Nine Months Ended September 30, September 1 to September 30, January 1 to August 31, 2018 2017 2017 Cash purchases of property and equipment, net: Surgical facility services $ 21,590 $ 1,613 $ 14,582 Ancillary services 334 2 1,875 Optical services 42 23 73 All other 4,652 202 2,243 Total cash purchases of property and equipment, net $ 26,618 $ 1,840 $ 18,773